论文部分内容阅读
急性髓系白血病(AML)占急性白血病的60%～70%。AML患者初诊时约存在1012的白血病细胞,而经过化疗达完全缓解(CR)后仍存在相当数量(可达108～1010)的白血病细胞,这些细胞成为疾病复发的根源,称为微小残留病(MRD)。目前AML的治疗主要根据遗传学(细胞遗传学和分子生物学)特征进行危险度分层治疗,越来越多的证据表明将MRD监测的结果纳入危险程度分层的标准或根据MRD监测情况进行动态的危险度分组、给予相应的治疗干预,对患者缓解后的治疗有着更加实际的意义。
Acute myeloid leukemia (AML) accounts for 60% to 70% of acute leukemia. There are about 1012 leukemic cells in AML patients, and there are still a considerable number (up to 108-1010) of leukemia cells after chemotherapy for complete remission (CR). These cells become the root cause of disease recurrence and are called minimal residual disease MRD). At present, the treatment of AML is mainly based on the characteristics of genetics (cytogenetics and molecular biology) risk stratification treatment, more and more evidence that the results of MRD monitoring included in the risk stratification criteria or according to MRD monitoring Dynamic risk grouping, given the appropriate treatment intervention, the treatment of patients with remission has a more practical significance.